- NAD+ is an essential coenzyme in redox reactions, mitochondrial function, and sirtuin and PARP enzyme activity, which places it at the intersection of many aging-related pathways studied in the literature.
- Human trials of NAD-boosting compounds have enrolled women, but across the indexed literature few of those studies reported outcomes stratified by sex.
- No menstrual cycle interaction data, no pregnancy or lactation safety data, and no characterized hormonal interactions exist for supplemental NAD+, leaving several female-relevant questions unstudied.
Read enough metabolic-aging research and one compound keeps appearing at the center of the diagram: NAD+, nicotinamide adenine dinucleotide, an essential coenzyme present in every living cell. It is built from two nucleotides joined through their phosphate groups, and its central role in cellular metabolism has made it a foundational tool compound in energy and aging research rather than a novelty. What is far less settled is how the human evidence, thin as it still is, breaks down by sex.
That gap is worth naming up front because NAD+ sits at a place in physiology where sex differences would be plausible. It ties together energy metabolism and enzymatic signaling in a way that connects many aging-related pathways to a single coenzyme, and several of those pathways interact with hormonal state. Yet most of the underlying research was not designed to report whether women and men responded differently.
What NAD+ is studied for
In cellular and preclinical models, NAD+ has been studied for its role in redox reactions, in mitochondrial electron transport, and as a substrate for sirtuin and PARP enzymes involved in DNA-repair and gene-regulation signaling. Researchers examining cellular-energy and aging models have used NAD+ and its precursors as research materials to probe how NAD availability shapes metabolic and repair pathways. The framing here is mechanistic and associative; these are pathways studied in models, not demonstrated human outcomes.
What makes NAD+ notable for a longevity catalog is exactly this convergence. Instead of one narrow mechanism, the coenzyme sits upstream of several, which is why NAD-boosting approaches have drawn sustained research interest. Whether raising NAD availability changes meaningful outcomes in people remains an open research question, and it is one this database tracks rather than resolves.
The female-evidence picture
Human trials of NAD-boosting compounds have enrolled women. That is the honest starting point, and it is better than the situation for many compounds in this database. The limitation is what happened next: across the indexed literature, many studies included women but few reported sex-stratified outcomes, so the female-specific signal was not extracted even when women were in the room.
Aging-research cohorts also include women in the perimenopausal and menopausal age range, but menopausal status is rarely analyzed as a variable. That leaves a no-evidence state rather than a reassuring one: women were present, but the question of whether menopausal transition changes NAD-related responses was not asked in a way the published record can answer.
- Menstrual cycle interactions: no data. Cycle-phase effects on NAD-related responses have not been characterized.
- Pregnancy and lactation: no safety data for supplemental NAD+. Absence of data is not evidence of safety.
- Hormonal interactions: none characterized in the indexed literature.
- Perimenopause and menopause: women are included in aging cohorts, but menopausal status is rarely analyzed.
- Sex differences: many studies included women; few reported outcomes by sex.
For NAD+, our review classifies the female-evidence type as extrapolated, meaning female-relevant conclusions would have to be inferred from mixed or male-weighted data rather than drawn from female-specific analysis. On dose, NAD+ and its precursors have been studied across a wide range in research, with no consensus therapeutic dose, which we report only as a description of the literature.
This site does not publish personal dosing. Any dose language here describes what appears in the research record for context only; it is not a protocol, a recommendation, or medical advice.
The through-line for NAD+ is the same lens we apply everywhere on this site: the mechanism is well described, women have been included in some human work, and the sex-specific reporting is still missing. If you want the structured evidence review and the field-by-field knowledge states, they live on the compound profile at NAD+.